Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 1, 2010, by Jazz Pharmaceuticals, Inc. The filing discloses the entry into a Material Definitive Agreement regarding the supply of sodium oxybate, the active pharmaceutical ingredient in the Company's product Xyrem.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual supply agreement.
Material Changes and Agreements
- New Supply Agreement: On April 1, 2010, the Company entered into a Supply Agreement with Siegfried (USA) Inc.
- Supply Obligations: Siegfried has the right to supply at least 60% and up to 100% of the Company's worldwide requirements for sodium oxybate.
- Alternative Sourcing: The Company retains the right to purchase up to 40% of its requirements from other suppliers, or additional amounts if Siegfried cannot fulfill orders.
- Pricing and Term: Pricing is volume-based. The agreement expires on April 1, 2015, with automatic three-year extensions unless terminated with 18 months' notice.
- Exclusivity: Siegfried is prohibited from manufacturing sodium oxybate for any other party during the term and for 18 months thereafter.
- Current Supplier Status: The current supplier, Lonza Inc., is closing its U.S. facility but remains contractually obligated to supply the Company through December 31, 2011.
Guidance, Risks, and Contingencies
- Regulatory Contingencies: Siegfried must register with the DEA, obtain a DEA quota, and receive FDA approval as a new supplier before commencing supply.
- Termination Right: The Company may terminate the agreement with 30 days' notice on or after December 31, 2011, if Siegfried fails to obtain required approvals or quotas for the 2011 calendar year.
- Risk Factors: The filing highlights risks related to dependence on single-source suppliers and the necessity of obtaining DEA quotas for the active pharmaceutical ingredient.
Investor Verification Checklist
- Verify Siegfried's progress in obtaining DEA registration and manufacturing quotas for sodium oxybate.
- Confirm FDA approval status for Siegfried as a new supplier of sodium oxybate.
- Monitor Lonza's ability to fulfill supply obligations through the December 31, 2011, contractual deadline.
- Review the full text of the Supply Agreement filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2010.